Telehealth Peptide Access: What Physicians Need to Know

The Telehealth Peptide Boom: Clinical Realities

The acceleration of telehealth platforms offering GLP-1 agonists, peptides, and hormone therapies represents a significant shift in access infrastructure—but not without clinical and regulatory friction. Karpa Health's launch exemplifies an industry trend: decentralizing what was previously gatekept by endocrinologists and anti-aging specialists. For practicing physicians, this matters. Your patients are finding these services.

Why Baseline Testing Matters More in Telehealth

Telehealth peptide providers operate in a compressed decision window. Without in-person examination, labs become the primary diagnostic anchor. This is where the stakes are highest.

Before any patient initiates growth hormone secretagogues (GHRH agonists like sermorelin, CJC-1295, or ipamorelin) or gonadotropin-releasing hormone (GnRH) analogs, baseline testing should include:

IGF-1: Establishes baseline GH axis responsiveness. Reference range 83–213 ng/mL varies by age; optimal for peptide therapy typically 150–250 ng/mL
Fasting glucose and HbA1c: GLP-1 agonists and other peptides alter insulin sensitivity and glucose clearance—starting values inform titration strategy
Complete lipid panel: GHRH agonists can modulate cholesterol synthesis via IGF-1–mediated pathways
TSH, free T3, free T4: Peptides and GH interact with thyroid hormone metabolism; baseline thyroid function prevents iatrogenic dysregulation
**Testosterone (total and free), estradiol (in men): Critical before GnRH or LHRH peptides
DHEA-S: Reflects adrenal reserve; important in protocols combining peptides with stress adaptation compounds like ashwagandha
Cortisol (AM fasting, optionally 4-point curve): Peptides that enhance GH release can modulate HPA axis tone
Liver function tests (AST, ALT, bilirubin): Hepatic metabolism of peptides varies; baseline establishes safety ceiling
Kidney function (creatinine, eGFR): Renal clearance of synthetic peptides requires monitoring
Complete blood count: Baseline hematologic status before any hormonal intervention

Telehealth providers who skip or minimize this panel are practicing substandard medicine. Push back. Demand it.

The Synergy Stack: What Works With Peptides

Patients on GHRH agonists, GLP-1s, or testosterone-stimulating peptides often ask about supplementation. The literature supports these adjuncts:

Magnesium Glycinate (400–500 mg daily): Supports GHRH release and cortisol regulation. Mechanism: glycine enhances sleep quality (when GH secretion is maximal), and magnesium acts as a cofactor in hundreds of enzyme systems including those governing glucose metabolism.

Zinc (15–25 mg daily, elemental): Required for testosterone synthesis and IGF-1 signaling. Deficiency blunts growth hormone response to secretagogues. Pairing with GHRH agonists requires adequate zinc status.

Vitamin D3 (2,000–4,000 IU daily) + K2 (90–180 mcg daily): D3 upregulates IGF-1 gene expression in bone and muscle. K2 prevents vascular calcification—a risk when IGF-1 rises acutely. Optimal vitamin D level for peptide therapy: 40–60 ng/mL.

Creatine Monohydrate (3–5 g daily): Synergizes with GHRH agonists to enhance muscle protein synthesis. IGF-1 + creatine improves phosphocreatine cycling in myocytes, accelerating strength gains. Safe for kidney function if baseline eGFR > 60.

Omega-3 (fish oil, 2–3 g EPA+DHA daily): Reduces systemic inflammation, which otherwise antagonizes peptide efficacy. GLP-1 agonists can suppress appetite; omega-3s preserve cardiovascular health during caloric restriction.

NAC (N-acetylcysteine, 600–1,200 mg daily): Glutathione precursor. Supports hepatic phase II detoxification during peptide therapy. Particularly relevant for patients on GLP-1 agonists, which can alter liver metabolism.

Collagen peptides (10–15 g daily): Provides glycine and proline; synergizes with GHRH agonists to enhance joint and skin collagen synthesis. Timing: post-workout or with vitamin C.

Ashwagandha (300–500 mg daily, standardized to 5% withanolides): Reduces cortisol spikes that otherwise antagonize GH release. Mechanism: binds glucocorticoid receptors, preventing excessive HPA axis activation during peptide therapy.

Berberine (500 mg, 2–3× daily): AMPK activator. Improves insulin sensitivity synergistically with GLP-1 agonists. Particularly useful in metabolic syndrome presentations.

Methylated B vitamins (B6 as pyridoxal-5-phosphate, B12 as methylcobalamin, folate as methylfolate): Support homocysteine metabolism and methylation reactions required for optimal IGF-1 signaling and testosterone synthesis.

Reading the Follow-Up Labs: What Changes Matter

After 8–12 weeks on peptides, repeat labs should show:

IGF-1: Expected rise of 20–50% (depends on secretagogue used; CJC-1295 produces larger gains than sermorelin)
Fasting glucose: Should remain stable or improve slightly, especially on GLP-1 agonists
HbA1c: In diabetic patients, expect 0.5–1.5% reduction over 3 months
Testosterone (in men): GnRH-based peptides should increase total testosterone 15–30%. If minimal rise, suspect inadequate baseline zinc, vitamin D, or protocol non-adherence
TSH: Should remain < 2.5 mIU/L. Rising TSH despite peptide therapy signals thyroid compensation and requires levothyroxine adjustment
Cortisol (AM): Should remain 10–20 mcg/dL. Elevations suggest inadequate recovery or ashwagandha dosing
Liver function: AST and ALT should not rise > 20% from baseline

The Telehealth Wild West

Not all telehealth peptide providers follow this protocol. Some:

Order minimal baseline labs (just lipids, maybe TSH)
Fail to re-test after 6–8 weeks
Don't adjust supplemental protocols based on lab changes
Mix peptides with other hormones (exogenous testosterone, thyroid hormone) without integrative endocrine modeling

This is liability exposure—both for the telehealth company and for any referring physician.

Bottom Line

Telehealth peptide platforms solve an access problem. But access without rigor is reckless. If your patients are using these services, insist on baseline and follow-up labs. Demand that their remote prescriber documents mechanism of action, baseline function, and re-testing intervals. The peptide itself is safe; the protocol execution is everything.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.